|
|
|
| Effect of Sargentodoxae Caulis combined with Maitong Powder exteral application on hemorheology and thrombolytic elasticity of lung cancer patients with lower extremity deep venous thrombosis |
| CHEN Hong WANG Wei LI Peifu XIAO Caizhi |
| Department of Traditional Chinese Medicine Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China |
|
|
|
Abstract Objective To investigate the effect of Sargentodoxae Caulis combined with Maitong Powder exteral application on hemorheology and thromboelastic elasticity of lung cancer patients with lower extremity deep venous thrombosis. Methods From July 2016 to July 2018, a total of 52 cases with lung cancer patients with lower extremity deep venous thrombosis were admitted to Chongqing University Cancer Hospital. According to the random number table method, they were divided into the treatment group and the control group, with 26 cases in each group. The control group was treated with Low Molecular Weight Heparin Calcium. The treatment group was treated with Sargentodoxae Caulis combined with Maitong Powder on the basis of the control group for 2 courses of treatment. Clinical efficacy, circumference diameter of affected limb difference, high blood viscosity (HBV), low blood viscosity (LBV), fibrinogen (FIB) and K value of thrombolytic elasticity were compared between the two groups. Results The total effective rate of the treatment group was significantly higher than that of the control group，and the difference was statistically significant (P < 0.05). The difference of 15 cm circumference between the upper and lower edges of the patella in the treatment group were lower than those in the control group, and the differences were statistically significant (P < 0.05). Before treatment, there was no significant difference with HBV, LBV and FIB levels in the two groups (P > 0.05). After treatment, the levels of HBV, LBV and FIB in the two groups were all lower than those before treatment, and the treatment group were lower than the control group, with statistically significant differences (P < 0.05). Before treatment, there was no significant difference in the K value of thrombolytic elasticity between the two groups (P > 0.05). After treatment, the K value of thrombolytic elasticity was higher than that before treatment, and the treatment group was higher than the control group, with statistically significant differences (all P < 0.05). Conclusion Sargentodoxae Caulis combined with Maitong Powder external application have a definite effect on patients with lung cancer with deep vein thrombosis of lower extremities, which can significantly improve hemorheology indexes and K value of thrombolytic elasticity, and it is worthy of clinical application.
|
|
|
|
|
|
[1] 隋丽丽，叶斯斯，白莉.90例肺癌合并下肢静脉血栓形成的临床特征分析[J].解放军医学院学报，2016，37（6）：595-598.
[2] Alexander M，Kirsa S，Wolfe R，et al. Thromboembolism in lung cancer-an area of urgent unmet need [J]. Lung Cancer，2014，84（3）：275-280.
[3] Elyamany G，Alzahrani AM，Bukhary E. Cancer-associated thrombosis：an overview [J]. Clin Med Insights Oncol，2014，8（8）：129-137.
[4] Stein PD，Beemath A，Meyers FA，et al. Incidence of venous thromboembolism in patients hospitalized with cancer [J]. Am J Med，2006，119（1）：60-68.
[5] 陈红，王维，肖彩芝.脉通散外敷联合低分子肝素钙治疗老年恶性肿瘤下肢血栓的疗效[J].中国老年学杂志，2016， 36（20）：5053-5055.
[6] 张阳德.血管外科诊疗手册[M].北京：人民军医出版社，2008：23-25.
[7] 黎涛，张忠德，侯庆荣，等.彩色多普勒血流显像对下肢静脉血栓的诊断价值[J].中国医药科学，2019，9（3）：134-136.
[8] 陈淑长.周围血管病中医研究最新全书[M].北京：中国医药科技出版社，1992：361-362.
[9] Chew HK，Davies AM，Wun T，et al. The incidence of venous thromboembol-ism among patients with primary lung cancer [J]. J Thromb Haemost，2008，6（4）：601-608.
[10] 曾凡，胡娟.肺癌患者住院时下肢深静脉血栓形成及相关危险因素分析[J].血栓与止血学，2019，25（4）：640-641.
[11] 杜晖，赵洪林，李梅，等.肺癌患者入院时下肢深静脉血栓的发生率及相关危险因素分析[J].中国肺癌杂志，2018， 21（10）：761-766.
[12] 艾明瑞，王艳青，赵培，等.温阳益气汤治疗肺癌伴发下肢深静脉血栓形成的临床疗效观察[J].光明中医，2016， 31（7）：961-962.
[13] 徐巧荔.肿瘤介入术后预防深静脉血栓症的临床护理效果[J].中外医学研究，2018，16（8）：107-108.
[14] 成曦，孙宝兰，苏张瑶，等.血栓调节蛋白在大鼠深静脉血栓模型中的表达及其意义[J].中国实验动物学报，2019， 27（2）：193-199.
[15] 郑科武.肿瘤患者PICC置管并发上肢静脉血栓的危险因素分析[J].中国现代医生，2018，56（7）：76-78.
[16] 胡月，唐冬.合并深静脉血栓形成对卵巢癌预后的影响[J].中国医药导报，2018，15（8）：96-99.
[17] Khorana AA，Dalal M，Lin J，et al. Incidence and predictors of venous thromboembolism（VTE）among ambulatory high-risk cancer patients undergoing chemotherapy in the United States [J]. Cancer，2013，119（3）：648-655.
[18] Huang H，Korn JR，Mallick R，et al. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortalit ：a retrospective database study [J]. J Thromb Thrombolysis，2012，34（4）：446-456.
[19] Blom JW，Osanto S，Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients：higher risk for adenocarcinoma than squamous cell carcinoma [J]. J Thromb Haemost，2004，2（10）：1760-1765.
[20] Agnelli G，Bolis G，Capussotti L，et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery：the @RISTOS project [J]. Ann Surg，2006，243（1）：89-95.
[21] Salla E，Dimakakos EP，Tsagkouli S，et al. Venous thromboembolism in patients diagnosed with lung cancer [J]. Angiology，2016，67（8）：709-724.
[22] 石玮玮，鲁丽莎，马士辉，等.中医特色疗法联合早期康复在老年股骨颈骨折术后下肢深静脉血栓随机平行对照研究[J].四川中医，2017，35（4）：203-206.
[23] 陈少兰，付成华.中西医护理在妇科恶性肿瘤术后下肢深静脉血栓形成的效果观察[J].四川中医，2016，34（10）：210-212.
[24] 陶诗友，洪瑶，徐德宝.深静脉血栓低分子肝素治疗中血栓弹力图和凝血指标分析的联合应用[J].现代检验医学杂志，2019，34（5）：150-152，164.
[25] 罗妍，金志军.低分子肝素钙在妇科肿瘤腹腔镜术后深静脉血栓预防中的效果观察[J].中国肿瘤临床与康复，2019，26（6）：652-655.
[26] 胡丹凤，黄礼年.低分子肝素在抗恶性肿瘤中的应用进展[J].中华全科医学杂志，2010，8（3）：353-354.
[27] 王振义，李家增.血栓与止血基础理论与临床[M].上海：上海科学技术出版社，2004：876-878. |
|
|
|
